Clinical Trial Update: Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating GL-0817 with cyclophosphamide for preventing recurrence of squamous cell carcinoma of the oral cavity has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Oral Cavity

Drugs mentioned

• GL-0817

Snippet

Sponsor: Gliknik Inc. | Conditions: Squamous Cell Carcinoma of the Oral Cavity | Phase 2 | Status: COMPLETED